Maleinsaeureanhydrid/Anthracen | 29268-27-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并呋喃类
• 英文名称: Maleinsaeureanhydrid/Anthracen
• 英文别名: Anthracene;furan-2,5-dione
• CAS: 29268-27-7
• 化学式: C₄H₂O₃*C₁₄H₁₀
• 分子量: 276.291
• InChiKey: SDZIUGJUASUIQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.62
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] ANTHRACENE BASED COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS À BASE D'ANTHRACÈNE ET LEURS UTILISATIONS
  申请人：UNIV OF HERTFORDSHIRE HIGHER EDUCATION CORP

  公开号：WO2016181120A1

  公开（公告）日：2016-11-17

  The present invention relates to compounds of the general formula (A) and their applicability for use in the treatment or prophylaxis of a disease, in particular for use as in treatment of cancer, in particular for use as in treatment of pancreatic cancer, in particular as inhibitors of S100P/RAGE interaction in pancreatic cancer. In summary herein are presented a group of compounds for use as in treatment of cancer, in particular as inhibitors of S100P/RAGE interaction in pancreatic cancer. The compounds have general formula (A): (A) or may be a pharmaceutically acceptable salt, solvate, hydrate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, stereoisomer or mixture thereof. X is independently NO2 or H; and Y is independently H or a side group. The compounds all have a lower fused ring system based on nitroanthracene or anthracene. The group Y attached to the N of the succinimide group varies between the compounds. For example, Y may be substituted or non-substituted benzene ring. Alternatively, in some examples Y is a heteroaromatic system. It has been discovered from studies by the inventors that the compounds described will inhibit S100P/RAGE interaction and are therefore useful for treating pancreatic cancer.

  本发明涉及一般式（A）的化合物及其在治疗或预防疾病方面的适用性，特别是在癌症治疗中的应用，特别是在胰腺癌治疗中的应用，特别是作为胰腺癌中S100P/RAGE相互作用的抑制剂。总之，这里介绍了一组化合物，用于癌症治疗，特别是作为胰腺癌中S100P/RAGE相互作用的抑制剂。这些化合物具有一般式（A）：（A）或者可能是药用可接受的盐、溶剂化合物、水合物、多晶形、前药、共药、共晶、互变异构体、拉氏体异构体或其混合物。X独立地是NO2或H；Y独立地是H或侧基。所有这些化合物都基于硝基蒽或蒽的较低融合环系统。连接到琥酰亚胺基团的N的Y基团在这些化合物之间变化。例如，Y可能是取代或非取代的苯环。另外，在某些例子中，Y是一个杂环芳香系统。发明者的研究表明，所描述的化合物将抑制S100P/RAGE相互作用，因此对治疗胰腺癌是有用的。
• Anthracene based compounds and their uses
  申请人：UNIVERSITY OF HERTFORDSHIRE HIGHER EDUCATION CORPORATION

  公开号：US10640466B2

  公开（公告）日：2020-05-05

  A compound of the general formula (A) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, stereoisomer or mixture thereof, in which: X is independently NO2 or H; and Y is selected from H, amino, amide, ester, carboxy and its esters and amides, alkyl, alkenyl, alkynyl, cycloalkyl, alkaryl, aryl, heterocyclic or heteroaryl groups, all of which can be substituted with heteroatoms and/or side groups, and wherein any chains can be straight or branched is disclosed.

  通式（A）的化合物 或其药学上可接受的盐、溶液剂、水合物、多晶型、原药、同系物、共晶体、同系物、外消旋体、立体异构体或混合物，其中X独立地为NO2或H；Y选自H、氨基、酰胺、酯、羧基及其酯和酰胺、烷基、烯基、炔基、环烷基、烷芳基、芳基、杂环基或杂芳基，所有这些基团均可被杂原子和/或侧基取代，其中任何链均可为直链或支链。
• ANTHRACENE BASED COMPOUNDS AND THEIR USES
  申请人：University of Hertfordshire Higher Education Corporation

  公开号：EP3294730A1

  公开（公告）日：2018-03-21
• US5025222A
  申请人：——

  公开号：US5025222A

  公开（公告）日：1991-06-18